DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors

Inclusion Criteria: * 1\. Previously untreated patients with histologically- or cytologically- documented NSCLC diagnosed with Pancoast tumor according to 8th edition of the TNM (stages IIB, IIIA and T3N2 (IIIB) patients) * 2\. PET/CT including IV contrast (CT of diagnostic quality) will be performed at baseline (28 days +10 before enrollment) to rule out the presence of distant disease. Also, a brain CT-SCAN or brain MRI will be done at baseline * 3\. Positive mediastinal lymph nodes by PET-CT must be confirmed histologically. Mediastinal involvement may be considered without the need for histological confirmation when there is a mass of lymph nodes in which the margins cannot be distinguished * 4\. Measurable or evaluable disease (according to RECIST 1.1 criteria) * 5\. ECOG (Performance status) 0-2 * 6\. Patients with a life expectancy of at least more than 12 weeks * 7\. Patients aged \> 18 years and ≤ 75 years * 8 Screening laboratory values must meet the study criteria and should be obtained within 14 days prior to enrollment * 9\. Correct lung function without bronchodilators, defined by forced expiratory volume in 1 second (FEV1) \>40% of the predicted normal volume, and a pulmonary diffusing capacity for carbon monoxide (DLCO) \>40% of the predicted normal value * 10\. All patients are notified of the investigational nature of this study and signed a written informed consent in accordance with institutional and national guidelines, including the Declaration of Helsi…